AVAnnette Vu

Annette Vu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annette Vu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Remote identification of new-onset paediatric atopic dermatitis: a comparison of diagnostic methods from a post hoc analysis of the CASCADE prevention trial

    by Milie M Fang, Jordan Gillespie, Robyn Okereke, Cynthia D Morris, Hywel C Williams, Mary F Henningfield, Donald E Nease, Rowena J Dolor, Katrina Ramsey, Annette Vu, et al.

    Background: Few validated diagnostic criteria for atopic dermatitis (AD) can diagnose AD without a clinician’s examination, and even fewer are validated in very young children. Recently, the Community-based Assessment of Skin Care, Allergies and Eczema (CASCADE) prevention trial remotely captured parent and caregiver responses to the Childhood Eczema Questionnaire (CEQ) and a Proxy Report of a Clinician AD Diagnosis (PRC-AD) in children ≤ 2 years of age. Objectives: To evaluate the performance of CEQ and PRC-AD for the purpose of remote AD diagnosis. Methods: Data from the CASCADE trial were used to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CEQ or PRC-AD at 12 and 24 months of age in 933 participants with data available for comparison against the reference standard of a clinician’s chart-diagnosis of AD, present in 26.2% (n = 244/933 at 24 months) of the cohort. Clinicians who acted as the reference standard were primary care clinicians or paediatricians who received additional training in diagnosing AD. Results: PRC-AD displayed sensitivity of 65.8% and 71.6%, and specificity of 91.3% and 93.2% at 12 months and 24 months, respectively. It also displayed PPV of 72.5% and 88.3%, and NPV of 88.5% and 82.2% at 12 and 24 months, respectively. In comparison, CEQ showed sensitivity of 46.3% and 50.9%, and specificity of 91.5% and 93.2% at 12 months and 24 months, respectively. It showed PPV of 64.5% and 84.1%, and NPV of 83.5% and 72.8% at 12 months and 24 months, respectively. A lack of proxy-observed or reported itch or rash were the most common reasons for CEQ false-negative cases. Conclusions: PRC-AD performed well for sensitivity, specificity, PPV and NPV, followed by CEQ. This study based in the USA provides new evidence that supports PRC-AD as an adequate approach to identify eczema cases remotely for research in children ≤ 2 years old with access to healthcare.